About
Generare, founded in 2023 in Paris, France, uses AI and synthetic biology to discover small molecules from microbial genomes for drug discovery.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesMedicine & PharmaMediumEvidence
利用 AI 与合成生物学从微生物基因组中发现 small molecules，用于 drug discovery
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-04Series A$23M
Investors · Daphni, Vives Partners, Galion.exe, Alven, Teampact VenturesSource · SVTR Weekly #151 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Generare
Small-molecule discovery driven by AI and synthetic biology
Series A · $46M · 2026-04
$46M
United States
BusinessLatest roundTotal raisedDate- Terray Therapeutics
Combines AI with wet lab science to discover new small-molecule drugs
Undisclosed · $120M · 2024-10
$120M - Integrated Biosciences
Drugs for age-related diseases developed with synthetic biology and AI
Seed · $17M · 2024-10
$17M - Excelsior Sciences
Machine-executable chemistry plus AI to speed small-molecule discovery and manufacturing; building the smart bloccs platform
Undisclosed · $70M · 2025-12
$70M
China
BusinessLatest roundTotal raisedDate- 中科欣扬
Synthetic biology platform built on extremophile microbial resources, developing bioactive ingredients for the pharmaceutical, food and cosmetics industries; commercialized products include ergothioneine, NMN and vanillin.
Series C · $42M · 2026-07
$42M - TandemAI
Drug molecule discovery platform rebuilt around "AI + physics-based modeling + wet lab"
Series A · $80M · 2025-11
$80M - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Enodia Therapeutics
Proteomics and machine learning-based small-molecule targeted protein degradation (TPD) platform
Seed · $25M · 2026-01
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - OlsAro
AI-driven discovery and breeding of climate-resilient crop traits
Seed · $9M · 2026-10
$9M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 26 at a nearby stage · 1 in Western Europe
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 10 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 9 at a nearby stage · 3 in Western Europe
Request intro →LifeX Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Western Europe
Request intro →Index Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.